Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* chronic renal anemia;~* on dialysis therapy for at least 12 weeks before screening;~* receiving IV epoetin for at least 8 weeks before screening.~Exclusion Criteria:~* women who are pregnant, breastfeeding or using unreliable birth control methods;~* administration of another investigational drug within 4 weeks before screening, or during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RO0503821 (1x/2 Weeks) (Type: EXPERIMENTAL): Participants received RO0503821 (Mircera \[methoxy polyethylene glycol-epoetin beta\]) once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 microgram \[mcg\]) that was based on the Epoetin dose (\<8000, 8000-16000, \>16000 International units \[IU\]/Week) administered during the week preceding the switch to the study drug.
- RO0503821 (1x/4 Weeks) (Type: EXPERIMENTAL): Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (\<8000, 8000-16000, \>16000 IU/Week) administered during the week preceding the switch to the study drug.
- Epoetin (1-3x/Weeks) (Type: ACTIVE_COMPARATOR): Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).